Tafamidis
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Tafamidis |
| DrugBank ID | DB11644 |
| Brand Names (EU) | Vyndaqel |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 89.27% |
Approved Indication (EMA)
Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary release disorder of platelets | 89.27% | DL |
| 2 | thrombocytopenic purpura | 88.73% | DL |
| 3 | pseudo-von Willebrand disease | 87.88% | DL |
| 4 | Glanzmann thrombasthenia | 85.79% | DL |
| 5 | primary amyloidosis | 85.00% | DL |
| 6 | acquired amyloid peripheral neuropathy | 84.77% | DL |
| 7 | primary hyperoxaluria | 84.33% | DL |
| 8 | dermis disease | 83.36% | DL |
| 9 | biotin metabolic disease | 83.32% | DL |
| 10 | mixed-type autoimmune hemolytic anemia | 82.31% | DL |
| 11 | drug-induced autoimmune hemolytic anemia | 81.98% | DL |
| 12 | proteinuria | 81.75% | DL |
| 13 | inherited thrombophilia | 80.98% | DL |
| 14 | amyloidosis cutis dyschromia | 80.80% | DL |
| 15 | nodular cutaneous amyloidosis | 80.80% | DL |
| 16 | macular amyloidosis | 80.80% | DL |
| 17 | neonatal autoimmune hemolytic anemia | 80.72% | DL |
| 18 | Ledderhose disease | 80.42% | DL |
| 19 | familial apolipoprotein C-II deficiency | 78.49% | DL |
| 20 | infantile digital fibromatosis | 78.16% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.